China’s role in U.S. pharma supply chain problems

    China’s role in U.S. pharma supply chain problems

    First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them. You can submit a…

    Read More
    STAT+

      The China biotech backlash in the U.S. has troubling undertones

      I spent nearly two decades covering the biotech and pharma sector, first in Washington, D.C., and then in Beijing. My first story, published in 2007, covered the U.S. Food and Drug Administration’s decision to open its inaugural overseas office in China, a fast-emerging market I later covered for 12 years. In that time, I saw…

      Read More
      A two-story interior with many windows features a mural with the word “Pyrotech” and a logo of 10 circles arranged in a circle.

        How Chinese labs race for the next ‘first-in-class’ breakthrough

          Key Insights China’s researchers are racing to close the country’s gap with the US in chemistry-related advancements and secure the next frontier of innovations in materials, energy, and biomedicine. Increasing funding pools, investments in health-system reforms, and innovation-driven policies, such as integrating medical insurance data into R&D, are accelerating the rate of China’s gain in developing novel drugs, according…

        Read More